Document Detail


Ticagrelor.
MedLine Citation:
PMID:  20502721     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Coronary artery disease (CAD) is the single leading cause of death in the U.S. Therapies for CAD have been developed to inhibit platelet aggregation underlying atherogenesis. Clinical benefit has been shown with antagonists of the P2Y(12) receptor, such as clopidogrel. However, concerns over patient resistance to treatment and relatively slow onset and offset of action have indicated the need for further pharmacotherapeutic development. Ticagrelor (formally AZD-6140) is a novel, reversible oral P2Y(12) antagonist developed by AstraZeneca. In vitro and in vivo studies have confirmed that ticagrelor provides rapid, enhanced and maintained antiplatelet effects. These findings have translated to clinical trial investigations with further evidence for a significantly reduced mortality rate associated with cardiovascular events, myocardial infarction (MI) or stroke, and a favourable safety profile. Key clinical trials to date include the DISPERSE, DISPERSE2, PLATO, ONSET/OFFSET and RESPOND. Ticagrelor has been put forward for approval to the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) as an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome.
Authors:
Shelley L Davies
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  46     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-05-26     Completed Date:  2010-08-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  243-50     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.
Affiliation:
Institute of Science and the Environment, University of Worcester, Worcester, UK. s.davies@worc.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / drug therapy,  physiopathology
Adenosine / analogs & derivatives*,  pharmacology
Administration, Oral
Animals
Clinical Trials as Topic
Coronary Artery Disease / drug therapy*,  physiopathology
Humans
Platelet Aggregation Inhibitors / pharmacology*
Receptors, Purinergic P2 / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/AZD 6140; 0/Platelet Aggregation Inhibitors; 0/Receptors, Purinergic P2; 0/purinoceptor P2Y12; 58-61-7/Adenosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Belatacept in clinical and experimental transplantation - progress and promise.
Next Document:  Zonisamide: a new drug for Parkinson's disease.